GlassScriptPhysician profile
Anna Sullivan Bruton
NPI 1023354024
$2,344.00
in general payments reported to CMS, 2019-2025
27 companies · $841 in 2025
The $841 reported for 2025 was more than what 82% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $212 · 2022: $240 · 2023: $403 · 2024: $648 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,891.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $515.04 | 2023-2025 | |
| Novo Nordisk INC | $392.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $287.36 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $125.62 | 2021-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.21 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $99.99 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Otsuka America Pharmaceutical, INC. | $94.31 | 2022-2023 | Rexulti |
| Abbott Laboratories | $83.80 | 2021-2025 | Proclaim, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.25 | 2021-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $60.55 | 2024 | Airsupra |
| Medtronic, INC. | $52.44 | 2024 | Intellis Adaptivestim |
| Scilex Pharmaceuticals INC. | $42.39 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $41.53 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $36.15 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.81 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $34.27 | 2022 | |
| Pfizer INC. | $31.59 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $31.13 | 2021-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $27.13 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $26.66 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $23.91 | 2021 | |
| Corium, LLC | $22.78 | 2023 | Azstarys |
| Astellas Pharma US INC | $21.82 | 2024 | Veozah |
| Sumitomo Pharma America, INC. | $18.39 | 2025 | Gemtesa |
| Eisai INC. | $17.73 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.29 | 2023 | Lifevest |
| Mylan Specialty L.P. | $15.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Bruton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.